Arvind Remedies Peer Comparison

NSE: ARVINDREM | BSE: 531823

₹4.70

₹-0.24 (-4.86%)

As on 13-Jun-2016IST

Market cap

₹32 Cr

Revenue (TTM)

₹12 Cr

P/E Ratio

P/B Ratio

-0.2

Div. Yield

0 %

Edit

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	32	35,548	28,659	28,019	28,577
Revenue (₹ Cr)	12	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-137.36	414.00	288.22	387.35	-371.81
Net Margin (%)	-1,121.27	11.23	14.79	26.01	-3.93
RoE (%)	--	8.38	29.77	25.18	-3.85
Price to Earnings	--	86.91	99.43	72.55	--
Price-To-Book	-0.20	7.06	21.35	16.24	3.57

Income Statement (₹ Cr)

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	962.68	4,830.36	41.58	76.11	--
Total Income	963.22	4,914.64	41.73	76.68	--
Total Expenditure	781.32	3,850.53	30.00	69.99	--
EBITDA	181.36	979.83	11.59	6.12	--
Depreciation	14.34	139.92	3.35	0.80	--
EBIT	167.03	839.91	8.24	5.32	--
Interest	78.51	83.35	2.34	1.58	--
Other Income	0.54	84.28	0.14	0.56	--
Exceptional Items	--	49.83	--	--	--
Profit before Tax	89.05	890.67	6.04	4.31	--
Provision for Tax	28.69	47.88	1.54	1.44	--
Profit after Tax	60.36	842.79	4.50	2.86	--

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	283.06	3,581.47	44.83	10.77	--
Minority Interest	4.85	136.17	--	--	--
Non-Current Liabilities	288.00	1,161.18	10.36	1.29	--
Current Liabilities	547.46	1,743.20	21.34	26.33	--
Total Liabilities	1,123.36	6,622.02	76.53	38.71	--

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	433.26	3,266.10	51.75	7.38	--
Current Assets	690.11	3,355.92	24.78	31.01	--
Total Assets	1,123.36	6,622.02	76.53	38.71	--
Total Debt*	640.97	1,906.08	21.09	12.17	--
Net Current Assets	142.65	1,612.72	3.44	4.68	--
Contingent Liabilities	1.20	267.40	4.70	--	--

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	-65.08	1,476.29	6.29	-0.21	--
Cash Flow from Investing Activities	-24.64	-851.62	-5.46	-2.00	--
Cash from Financing Activities	71.24	-601.32	-0.58	2.17	--
Net Cash Inflow / Outflow	-18.48	23.35	0.25	-0.04	--

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	20.48	18.98	13.38	29.97	--
ROE (%)	26.81	30.04	19.08	30.26	--
ROA (%)	6.07	13.36	6.16	8.85	--
EBIT Margin (%)	18.90	22.03	28.21	8.78	--
Net Margin (%)	6.27	17.15	10.78	3.74	--
Cash Profit Margin (%)	7.33	20.32	18.86	4.81	--

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	36.34	-13.89	12.11	37.10	--
EBIT Growth (%)	28.76	-49.66	21.82	30.95	--
Net Profit Growth (%)	34.25	-46.64	58.36	39.55	--
EPS Growth (%)	-4.56	-56.04	58.36	39.55	--
Book Value Growth (%)	57.80	36.37	21.09	32.03	--

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	5.03	6.59	0.00	0.00	--
Price / Book Value	1.07	1.55	0.00	0.00	--
Dividend Yield (%)	1.85	2.19	--	--	--
EV/EBITDA	5.11	5.73	3.52	2.02	--
Market Cap (₹ Cr)	293.96	5,016.58	0.00	0.00	--

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	2.33	0.54	0.47	1.13	--
Short term debt to equity ratio	1.22	0.06	0.23	0.84	--
Current Ratio	1.26	1.93	1.16	1.18	--
Quick Ratio	0.90	1.36	1.11	0.75	--
Interest Coverage	2.13	11.69	3.58	3.73	--

	Arvind Remedies	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	36.39	9.96	33.85	17.81	--
Asset Turnover	1.02	0.77	0.57	2.35	--
Receivable days	109.13	54.33	106.93	58.46	--
Inventory Days	58.18	77.43	10.49	41.85	--
Payable days	41.26	120.43	213.33	91.25	--
Cash Conversion Cycle	126.04	11.32	-95.91	9.06	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.